| __timestamp | Agios Pharmaceuticals, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 21226345 |
| Thursday, January 1, 2015 | 141827000 | 139626 |
| Friday, January 1, 2016 | 220163000 | 93831530 |
| Sunday, January 1, 2017 | 292681000 | 79419009 |
| Monday, January 1, 2018 | 1397000 | 368673 |
| Tuesday, January 1, 2019 | 1317000 | 477121 |
| Wednesday, January 1, 2020 | 2805000 | 1895029 |
| Friday, January 1, 2021 | 18777000 | 8034589 |
| Saturday, January 1, 2022 | 1704000 | 20443000 |
| Sunday, January 1, 2023 | 9504000 | 33745000 |
| Monday, January 1, 2024 | 4165000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, understanding financial trends is crucial. This analysis compares the cost of revenue for Intra-Cellular Therapies, Inc. and Agios Pharmaceuticals, Inc. from 2014 to 2023. Agios Pharmaceuticals, Inc. experienced a significant decline in cost of revenue, dropping by approximately 90% from its peak in 2017 to 2022. In contrast, Intra-Cellular Therapies, Inc. saw a steady increase, with costs rising by over 50% from 2020 to 2023. This divergence highlights differing strategic approaches: Agios appears to be optimizing its operations, while Intra-Cellular is potentially expanding its market reach. These trends offer a glimpse into the evolving landscape of the biotech industry, where financial agility and strategic foresight are key to success.
Analyzing Cost of Revenue: Novo Nordisk A/S and Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Merck & Co., Inc. and Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Zoetis Inc. and Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: Teva Pharmaceutical Industries Limited vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Corcept Therapeutics Incorporated vs Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: Cytokinetics, Incorporated vs Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Agios Pharmaceuticals, Inc. vs Galapagos NV
Cost of Revenue: Key Insights for Agios Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.